Guggenheim issues buy rating for Yarrow Bioscience, sets price target at $60
YARW Yarrow Bioscience Inc
$15.79 +1.22%
View chart & analysis → - 1Yarrow Bioscience, Inc. shares rose 4.3% on Friday.
- 2Guggenheim initiated coverage with a $60 price target.
- 3The firm noted an estimated Graves' disease market size of $15 billion to $20 billion.
So what's the key point?
Guggenheim has started analyzing Yarrow Bioscience and predicts the stock price could reach $60. The firm reports that the market for the disease the company treats is worth up to $20 billion.
Source Investing.com · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.